Anticoagulation Forum/LinkedIn
Jun 22, 2026, 15:08
Apixaban vs. Rivaroxaban in Acute VTE – Uncoiling COBRRA and Its Clinical Implications – Anticoagulation Forum
Anticoagulation Forum shared a post on LinkedIn:
“Recording now available!
We are grateful to our expert faculty for sharing their time, and their thoughtful discussions, and insights during our recent webinar:
Apixaban vs. Rivaroxaban in Acute VTE: Uncoiling COBRRA and Its Clinical Implications
This session explored the clinical questions behind the COBRRA trial, including retrospective evidence, potential pharmacologic explanations, study design, key findings, and practical implications for frontline VTE care.
Faculty:
- Arthur Allen, PharmD
- Lana Castellucci, MD
- Steven Deitelzweig, MD
- Jori May, MD
If you missed the live webinar, want to revisit the discussion, or know a colleague who may benefit, the recording is available to watch for free on our Archived Webinars page.
-
Jun 22, 2026, 14:41Ilkin Aygun Soyalp: Novel Substrate Recognition Broadens the Biological Role of DPF-3
-
Jun 22, 2026, 14:29Swarnava Roy: Linking Angiotensin Signaling to Oxidative Stress and Organ Damage in Sickle Cell Anemia
-
Jun 22, 2026, 14:14Nicolò Vianini: New Evidence Confirms Bone Marrow as the Primary Site of Thrombopoiesis
-
Jun 22, 2026, 14:11Param Darpan Sheth: Revealing the Evolving Burden of MI and Heart Failure Mortality in the US
-
Jun 22, 2026, 13:56Eiman Emran: The Hematologic Consequences of Heavy Menstrual Bleeding
-
Jun 22, 2026, 13:47Isaac Okello: A Unified Voice for Sickle Cell Disease in Uganda
-
Jun 22, 2026, 13:40Anupama Krishnamoorthi: Inspiring the Next Generation of Haematologists
-
Jun 22, 2026, 13:39Heghine Khachatryan: The Inflammatory Engine Behind Venous Thrombosis
-
Jun 22, 2026, 13:35Aryabhatta Sadhu: Which Part of Haemostasis Has Failed First?